Actively Recruiting
Phase II Study of BL-M07D1 Combined With Pembrolizumab for Locally Advanced or Metastatic HER2-Positive Non-Squamous Non-Small Cell Lung Cancer
Led by Sichuan Baili Pharmaceutical Co., Ltd. · Updated on 2026-03-05
80
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the safety and effectiveness of combining BL-M07D1 with pembrolizumab in patients who have locally advanced or metastatic non-squamous non-small cell lung cancer that overexpresses HER2. This Phase II, open-label, multicenter study aims to better understand how these treatments work together in this specific patient group. Participants receive BL-M07D1 and pembrolizumab through intravenous infusions every three weeks. Those who show clinical benefit may continue with additional treatment cycles. Treatment will stop if the disease progresses, if side effects become intolerable, or for other reasons determined by the study team. During the study, patients will be closely monitored for treatment response using measures like the objective response rate, progression-free survival, and overall survival over about 24 months. Researchers will also track drug levels, immune responses, and any side effects. Participants will have regular assessments to ensure safety and evaluate how well the combination treatment works.
CONDITIONS
Brief Title
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC
Research Team
S
Sa Xiao, PHD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here